These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 19006678

  • 1. A cross-sectional, mono-centric pilot study of insulin resistance in enzyme replacement therapy patients with Gaucher type I without overweight.
    Ucar SK, Coker M, Argin M, Akman S, Kara S, Simsek DG, Darcan S.
    Mol Genet Metab; 2009 Jan; 96(1):50-1. PubMed ID: 19006678
    [Abstract] [Full Text] [Related]

  • 2. Overweight, insulin resistance and type II diabetes in type I Gaucher disease patients in relation to enzyme replacement therapy.
    Langeveld M, de Fost M, Aerts JM, Sauerwein HP, Hollak CE.
    Blood Cells Mol Dis; 2008 Jan; 40(3):428-32. PubMed ID: 17950007
    [Abstract] [Full Text] [Related]

  • 3. Histologic findings of femoral heads from patients with Gaucher disease treated with enzyme replacement.
    Lebel E, Elstein D, Peleg A, Reinus C, Zimran A, Amir G.
    Am J Clin Pathol; 2013 Jul; 140(1):91-6. PubMed ID: 23765538
    [Abstract] [Full Text] [Related]

  • 4. Enzyme replacement therapy in pediatric patients with Gaucher disease: what should we use as maintenance dosage?
    Brunel-Guitton C, Rivard GE, Galipeau J, Alos N, Miron MC, Therrien R, Mitchell G, Lapierre G, Lambert M.
    Mol Genet Metab; 2009 Feb; 96(2):73-6. PubMed ID: 19083253
    [Abstract] [Full Text] [Related]

  • 5. The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease.
    Charrow J, Dulisse B, Grabowski GA, Weinreb NJ.
    Clin Genet; 2007 Mar; 71(3):205-11. PubMed ID: 17309642
    [Abstract] [Full Text] [Related]

  • 6. [Enzyme replacement therapy in Gaucher disease: monitoring visceral and bone changes with MRI].
    Tóth J, Szücs FZ, Benkö K, Maródi L.
    Orv Hetil; 2003 Apr 20; 144(16):749-55. PubMed ID: 12778625
    [Abstract] [Full Text] [Related]

  • 7. [French results of enzyme replacement therapy in Gaucher's disease].
    Schaison G, Caubel I, Belmatoug N, Billette de Villemeur T, Saudubray JM.
    Bull Acad Natl Med; 2002 Apr 20; 186(5):851-61; discussion 861-3. PubMed ID: 12412377
    [Abstract] [Full Text] [Related]

  • 8. Prospects for enzyme replacement therapy in Gaucher disease.
    Brady RO, Barranger JA, Furbish FS, Stowens DW, Ginns EI.
    Prog Clin Biol Res; 1982 Apr 20; 95():669-80. PubMed ID: 7122643
    [No Abstract] [Full Text] [Related]

  • 9. Platelet function and coagulation abnormalities in type 1 Gaucher disease patients: effects of enzyme replacement therapy (ERT).
    Giona F, Palumbo G, Amendola A, Santoro C, Mazzuconi MG.
    J Thromb Haemost; 2006 Aug 20; 4(8):1831-3. PubMed ID: 16879228
    [No Abstract] [Full Text] [Related]

  • 10. Outcome of enzyme replacement therapy in Turkish patients with Gaucher disease: does late intervention affect the response?
    Arikan-Ayyildiz Z, Yüce A, Emre S, Baysoy G, Saltik-Temizel IN, Gürakan F.
    Turk J Pediatr; 2011 Aug 20; 53(5):499-507. PubMed ID: 22272449
    [Abstract] [Full Text] [Related]

  • 11. [Gaucher's disease and enzyme replacement therapy].
    Cornu F.
    Ann Pharm Fr; 1998 Aug 20; 56(3):102-7. PubMed ID: 9770016
    [Abstract] [Full Text] [Related]

  • 12. Long term effects of enzyme replacement therapy in an Italian cohort of type 3 Gaucher patients.
    Sechi A, Deroma L, Dardis A, Ciana G, Bertin N, Concolino D, Linari S, Perria C, Bembi B.
    Mol Genet Metab; 2014 Nov 20; 113(3):213-8. PubMed ID: 25127542
    [Abstract] [Full Text] [Related]

  • 13. [Gaucher disease: MR evaluation of bone marrow features during treatment with enzyme replacement].
    Poll LW, vom Dahl S, Koch JA, Börner D, Willers R, Cohnen M, Jung G, Scherer A, Niederau C, Häussinger D, Mödder U.
    Rofo; 2001 Oct 20; 173(10):931-7. PubMed ID: 11588682
    [Abstract] [Full Text] [Related]

  • 14. Gaucher disease: a century of delineation and research. Enzyme replacement therapy: model and clinical studies.
    Beutler E, Dale GL.
    Prog Clin Biol Res; 1982 Oct 20; 95():703-16. PubMed ID: 7122644
    [Abstract] [Full Text] [Related]

  • 15. Delayed growth and puberty in patients with Gaucher disease type 1: natural history and effect of splenectomy and/or enzyme replacement therapy.
    Kauli R, Zaizov R, Lazar L, Pertzelan A, Laron Z, Galatzer A, Phillip M, Yaniv Y, Cohen IJ.
    Isr Med Assoc J; 2000 Feb 20; 2(2):158-63. PubMed ID: 10804944
    [Abstract] [Full Text] [Related]

  • 16. Liposomes in Gaucher type I disease: use in enzyme therapy and the creation of an animal model.
    Gregoriadis G, Weereratne H, Blair H, Bull GM.
    Prog Clin Biol Res; 1982 Feb 20; 95():681-701. PubMed ID: 6812092
    [No Abstract] [Full Text] [Related]

  • 17. Early achievement and maintenance of the therapeutic goals using velaglucerase alfa in type 1 Gaucher disease.
    Elstein D, Cohn GM, Wang N, Djordjevic M, Brutaru C, Zimran A.
    Blood Cells Mol Dis; 2011 Jan 15; 46(1):119-23. PubMed ID: 20727796
    [Abstract] [Full Text] [Related]

  • 18. Acid beta-glucosidase: insights from structural analysis and relevance to Gaucher disease therapy.
    Kacher Y, Brumshtein B, Boldin-Adamsky S, Toker L, Shainskaya A, Silman I, Sussman JL, Futerman AH.
    Biol Chem; 2008 Nov 15; 389(11):1361-9. PubMed ID: 18783340
    [Abstract] [Full Text] [Related]

  • 19. Enzyme replacement therapy for Gaucher Disease: the only experience in Malaysia.
    Chan LL, Lin HP.
    Med J Malaysia; 2002 Sep 15; 57(3):348-52. PubMed ID: 12440275
    [Abstract] [Full Text] [Related]

  • 20. Gaucher disease with nephrotic syndrome: response to enzyme replacement therapy.
    Santoro D, Rosenbloom BE, Cohen AH.
    Am J Kidney Dis; 2002 Jul 15; 40(1):E4. PubMed ID: 12087590
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.